Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Galantos Pharma receives research grant
Expansion of technology platform


Mainz, May 28, 2008 – Galantos Pharma GmbH, a biopharmaceutical company developing natural product derivatives to treat Alzheimer’s disease (AD) today announced that it has been granted EUR 366.000 from Investitions- und Strukturbank Rheinland-Pfalz (ISB) GmbH, the investment and economic development bank of the German federal state of Rheinland-Pfalz. The grant was awarded under the technology development program of the ISB as a non-repayable grant covering part of the technology platform development effort of Galantos Pharma.

“The funds will allow us to expand our technology platform for the optimization of compounds targeting nicotinic acetylcholine receptors with subunit specificity and selectivity against muscarinic acetylcholine receptors“, said Dr Andreas Köpke, managing director and CBO of Galantos Pharma. “These compounds have considerable use in Alzheimer’s disease and other psychiatric indications.”

G alantos Pharma is optimizing an approved Alzheimer’s medication for improved brain penetration and reduced side effect profile as well as exploring two neuroprotective drugs – an allosteric potentiating ligand (APL) targeting nicotinic acetylcholine receptors in general (nAChRs) and a subtype-specific APL targeting the α7- subunit of nicotinic acetylcholine receptors.

APLs enhance the sensitivity of receptors and therefore overcome the well-established shortcomings of direct agonists, which are receptor desensitization and down-regulation of expression. Nicotinic acetylcholine receptors are widely distributed on neurons and other cells in the central nervous system and are involved in the regulation of cell survival and programmed cell death. It is also known that these receptors are increasingly lost in Alzheimer’s Disease. Results in animal models indicate that enhancing the sensitivity of nAChRs has considerable therapeutic potential in AD and other CNS-related diseases.

The lead candidate of Galantos Pharma is Memogain, a derivative of galantamine, a nicotinic acetylcholine receptor sensitizer and weak choline esterase inhibitor, which is already marketed for the treatment of AD since 2000 (EU) and 2001 (USA) respectively. Memogain offers improved efficacy at reduced adverse events and is expected to move into clinical development in Alzheimer’s disease (AD) in 2009.

Fur further details, please visit our website www.galantos.com.

About Galantos Pharma GmbH
Galantos Pharma GmbH, which was founded in 2005, is developing innovative drugs for the treatment of neurodegenerative diseases and is focused on the improvement of marketed drugs and natural substances for the treatment of Alzheimer’s Disease. The company has raised a total of EUR 3.5 million in two financing rounds.

Contact:
Dr. Andreas Köpke, CBO
Galantos Pharma GmbH
Freiligrathstr. 12
D-55131 Mainz
Germany
Tel.: +49(6131)1440-311
E-mail: info@galantos.com


Publisher Contact Information:

Galantos Pharma
+49(6131)1440-311
info@galantos.com

Company profile of Galantos Pharma
Past press releases of Galantos Pharma.

Data


27,026
Tech investments
From our Online Data Service
17,443
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.